New combo therapy aims to protect transplanted kidneys
NCT ID NCT05938712
First seen May 04, 2026 · Last updated May 04, 2026
Summary
This pilot study tests whether combining two diabetes medications, dapagliflozin and semaglutide, can safely improve kidney function in 20 kidney transplant recipients. Participants take the drugs for 12 weeks while researchers measure kidney health markers. The goal is to find a better way to manage long-term kidney health after transplantation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.